Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 71205-731

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 71205-731). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-731-30 (Atorvastatin 40 mg 30 Bottle Label)

This is a description of a package of Atorvastatin Calcium 40mg tablets, a prescription medication used to lower cholesterol. The package contains 30 film-coated tablets manufactured by Intas Pharmaceuticals Limited in India and packaged by Proficient Rx LP in Thousand Oaks, California. The tablets are white to off-white, oval-shaped, and debossed with "FF3" on one side and plain on the other. The lot number is 00000 and the expiration date is listed as 00/00/00. The National Drug Code (NDC) for this specific product is 71205-731-30. There are warnings to keep the medication out of the reach of children and to store it between 20°-25°C (68°-77°F).*

FDA Label Image

Figure (Atorvastatin Calcium Figure 1)

FDA Label Image

Figure (Atorvastatin Calcium Figure 2)

The provided text appears to be a visualization of a study or experiment with a placebo control and the intervention of Atorvastatin over the course of four years. It includes a graph showing the cumulative hazard percentage over time for both groups, as well as statistical data indicating a significant reduction of hazard with Atorvastatin (HR=0.63, p=0.001). However, without further context or additional information, it is difficult to provide a more detailed description or interpretation of these results.*

FDA Label Image

Figure (Atorvastatin Calcium Figure 3)

The text provided represents a clinical study result. It shows the percentage of subjects who experienced events with the use of Atorvastatin 10 mg and 80 mg. Additionally, it indicates the hazard ratio and p-value of Atorvastatin 80 mg in comparison to the placebo group. The final part of the text illustrates a graph titled "Time to First Major Cardiovascular Endpoint," where the X-axis represents the number of years and the Y-axis shows the probability of the occurrence of the major cardiovascular endpoint. The study aimed to evaluate the efficacy of Atorvastatin in reducing cardiovascular events.*

FDA Label Image

Chemical Structure (Atorvastatin Calcium Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.